Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Portrayal of Hospital Alcohol Detoxification in France (Alcostop)

18. oktober 2021 oppdatert av: University Hospital, Montpellier

Portrayal of Hospital Alcohol Detoxifications and Factors Associated With Longer or Ulterior Hospitalizations in France From 2011 to 2020

Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients, their length and geographical repartition, etc… The investigators also aim to evaluate factors associated with longer stays or ulterior re-hospitalization for the same reason. Finally, The investigators aim to compare the stays by facility type.

Studieoversikt

Detaljert beskrivelse

Context:

In France, the consequences of excessive alcohol use are one of the primary reasons for hospitalization. When stopping the substance, patients with an alcohol use disorder can suffer from a potentially fatal alcohol withdrawal syndrome. To mitigate these risks, a withdrawal under medical supervision is possible, either in an outpatient setting or in hospital, where the detoxification can be programmed or imposed. In the course of an alcohol dependent patient's life, re-drinking is not exceptional and the patient may undergo several withdrawals during his or her life.

Psychiatric pathologies, especially anxiety and depression, are more frequent in these patients than in the rest of the population, just as can be somatic pathologies.e. Withdrawal accidents, represented by comital seizures and delirium tremens, can be critical.

In hospital detoxifications, studies do not show any benefit in continuing the stay beyond 10 days, except in the case of somatic or psychiatric complication. However, little information is available on the average length of stay for hospital alcohol detoxification.

Although alcohol dependence issues are very frequent and the resulting withdrawals are relatively common and associated with numerous comorbidities, little data exists at a national level in France.

The aim of this study is to describe these hospital detoxifications: course, duration, frequency and clinical and paraclinical characteristics of the patients. We also wish to analyze which characteristics are associated with longer stays or re-hospitalization and to compare the care according to the facility type.

Objectives:

Main:

- To describe the clinical, paraclinical, and stay characteristics of hospital alcohol detoxification in France

Secondary:

  • To describe the regional distribution of hospital alcohol detoxification
  • To evaluate whether certain clinical characteristics are associated with a longer hospital stays
  • To evaluate whether certain clinical characteristics are associated with subsequent re-hospitalization for the same reason
  • To compare the characteristics of patient stays by type of facility

Methods:

In this descriptive observational study using pre-existing data accessed via the PMSI (Programme de Médicalisation des Systèmes d'Information), we will use all hospital stays from 2011 to 2020 for alcohol detoxification in France, both in public and private settings.

For each hospital stay will be collected the length, the antecedents of hospital alcohol detoxification, clinical and psychiatric comorbidities, withdrawals complication, alcohol use complication, further examinations.

We will describe the stays using median and quartiles for continuous variables and number and percentage for dichotomous variables. For secondary objectives, we will use a multivariate linear regression model if the length of stay is normal, an ordinal regression model otherwise. The characteristics of the stays will be compared regarding the type of facility using univariate comparative tests: Chi² or Fisher for dichotomous variables and Student or Mann-Whitney for continuous variables.

Studietype

Observasjonsmessig

Registrering (Faktiske)

50000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Montpellier, Frankrike, 34295
        • Uhmontpellier

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

French patients hospitalized for alcohol detoxification from 2011 to 2020

Beskrivelse

Inclusion criteria:

Inclusion criteria:

  • French patients of at least 18 years old
  • Inpatients of a public or private care facility for alcohol detoxification
  • From 01/01/2011 to 12/31/2020
  • In a medical or psychiatric hospital

Exclusion criteria:

- age < 18 years

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Inpatients for alcohol detoxifications
French patients who were hospitalized for alcohol detoxification from 2011 to 2020
Stay for alcohol detoxification : routine care.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
description of age
Tidsramme: day 1 (At hospital inclusion)
Age at admission (in years), calculated by the difference of the year of admission and the year of birth through the PMSI.
day 1 (At hospital inclusion)
description of sex
Tidsramme: day 1 (At hospital inclusion)
Sex collected through the PMSI.
day 1 (At hospital inclusion)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
description of geographic code
Tidsramme: day 1 (At hospital inclusion)
Sex collected through the PMSI.
day 1 (At hospital inclusion)
description of CMU-C
Tidsramme: day 1 (At hospital inclusion)
CMU-C (universal complementary health insurance, collected through the PMSI.
day 1 (At hospital inclusion)
Length of stay
Tidsramme: During the stay (day 1 - day 15)
Length of stay (in days), calculated by the difference between the discharge date and the entry date, collected through the PMSI.
During the stay (day 1 - day 15)
Care establishment
Tidsramme: During the stay (day 1 - day 15)
Name and type of the care establishment, collected through the PMSI.
During the stay (day 1 - day 15)
Number of previous hospital detoxification stays in the studied period
Tidsramme: During the stay (day 1 - day 15)
Number of previous hospital detoxification stays in the studied period, collected through the PMSI.
During the stay (day 1 - day 15)
Psychiatric comorbidities
Tidsramme: During the stay (day 1 - day 15)
Psychiatric comorbidities (Major depression episode, anxiety, psychotic trouble, personality diseases), collected through the PMSI.
During the stay (day 1 - day 15)
Withdrawal complication
Tidsramme: During the stay (day 1 - day 15)
Withdrawal complications (delirium tremens, comitial seizures), collected through the PMSI.
During the stay (day 1 - day 15)
Further examination
Tidsramme: During the stay (day 1 - day 15)
Further examination (biology, imagery, etc…), collected through the PMSI.
During the stay (day 1 - day 15)
Re-hospitalization for same reason
Tidsramme: day 1
For each patient, and each stay, we will evaluate if the patient had an ulterior re-hospitalization for alcohol withdrawal. Collected through the PMSI.
day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Lionel MOULIS, University Hospital, Montpellier

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mai 2021

Primær fullføring (Faktiske)

30. august 2021

Studiet fullført (Faktiske)

30. august 2021

Datoer for studieregistrering

Først innsendt

6. juli 2021

Først innsendt som oppfylte QC-kriteriene

21. juli 2021

Først lagt ut (Faktiske)

22. juli 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. oktober 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. oktober 2021

Sist bekreftet

1. oktober 2021

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

NC

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere